Sarepta Therapeutics (SRPT) Cash from Restructuring (2016)
Sarepta Therapeutics (SRPT) posted quarterly Cash from Restructuring of $407000.0 for Q4 2016, up 51.3% quarter-over-quarter from $269000.0 in Q3 2016.
Powered by 
Analysis
Sarepta Therapeutics (SRPT) Cash from Restructuring (2016) Analysis & Trends
Sarepta Therapeutics' Cash from Restructuring history runs 1 years deep, the most recent figure standing at $407000.0 for Q4 2016.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Sarepta Therapeutics | 2.36 Bn | 1.57 Bn | 251.87 Mn |